Skip to Main Content

News of the first clearly successful clinical trial for a new Alzheimer’s disease treatment in two decades has brought hope, scrutiny, and skepticism to a field accustomed to disappointment. Whether that treatment is a meaningful advance or another false dawn depends on scientific details yet to be presented and corporate decisions still to be made.

Here are the burning questions left unanswered by the success of lecanemab, the latest Alzheimer’s treatment from Biogen and Eisai.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment